VP16

ApprovedSmall molecule

SSt. Anna Kinderkrebsforschung

VP16 is one of 102 small molecule programs targeting Lymphoblastic Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoblastic LymphomaActive, not recruiting

LymphomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Lymphoblastic LymphomaApproved

Active, not recruiting

LymphomaApproved

Active, not recruiting

Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

VP16

SSt. Anna Kinderkrebsforschung

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Zofran

Novartis

Preclinical

2 4

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 5

Nuvigil

NNuvo Research GmbH

Preclinical

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

PEG-Intron

Merck & Co.

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2/3Recruiting

Allogeneic Stem Cell Transplantation

NCT01949129

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Completed·GGoethe University·Phase 3·NCT02881086·1,023 enrolled

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199004·60 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Completed·GGoethe University·Phase 4·NCT00199056·225 enrolled

Allogeneic Stem Cell Transplantation2 trials

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01423747·400 enrolled

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 2/3·NCT01949129·1,800 enrolled

Lymphoblastic Lymphoma1 trial

German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Completed·JJohann Wolfgang Goethe University Hospital·Phase 4·NCT00199017·75 enrolled

Lymphoma1 trial

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

Completed·NNicola Goekbuget·Phase 4·NCT00199082·650 enrolled

Adolescent1 trial

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

Unknown status·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01423500·405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for VP16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VP16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VP16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Anna Kinderkrebsforschung company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SSt. Anna Kinderkrebsforschung

VP16

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Acute Lymphoblastic Leukemia3 trials

Allogeneic Stem Cell Transplantation2 trials

Lymphoblastic Lymphoma1 trial

Lymphoma1 trial

Adolescent1 trial

References

Drug Info

Quick Facts

Related News